Is brexpiprazole (vRAYLAR) approved for use in a 16-year-old patient who has already tried aripiprazole (Abilify) and risperidone without adequate response?

VRAYLAR (Brexpiprazole) is NOT FDA-approved for patients under 18 years old

VRAYLAR is only approved for adults (age 18 and older) for schizophrenia, bipolar disorder, and adjunctive treatment of major depressive disorder. The FDA drug label does not include any pediatric indications for patients under 18 years 1.

Key Points for Your 16-Year-Old Patient

FDA Approval Status

• Brexpiprazole received FDA approval in January 2020 for adolescents aged 13-17 years with schizophrenia through a pharmacokinetic bridging approach that extrapolated efficacy data from adult trials 2
• This approval was based on exposure-matching between pediatric and adult populations, plus safety data from long-term open-label studies in adolescents 2
• The FDA label provided 1 appears to be from 2026 but only lists adult indications, suggesting the pediatric approval may be limited or the label excerpt is incomplete

Clinical Considerations for Treatment-Resistant Cases

Since your patient has failed both aripiprazole (Abilify) and risperidone:

According to current schizophrenia treatment algorithms 3:

1. After failure of a D2 partial agonist (like Abilify), switch to amisulpride, risperidone, paliperidone, or olanzapine (with metformin)
2. After two adequate trials (4-6 weeks each at therapeutic doses with confirmed adherence), clozapine should be considered 3, 4
3. Clozapine is the only antipsychotic with documented superiority for treatment-resistant schizophrenia in both adults and adolescents 4

Important Caveats

Before proceeding to clozapine or off-label brexpiprazole:

• Confirm diagnosis during a medication-free period if possible—23% of very early-onset schizophrenia cases were misdiagnosed 4
• Verify true treatment failure: adequate dose, adequate duration (4-6 weeks minimum), and confirmed medication adherence 3, 4
• Rule out substance use, medical conditions, or other contributing factors 3

If Considering Off-Label Brexpiprazole

While brexpiprazole has pediatric approval for schizophrenia in 13-17 year-olds based on the extrapolation approach 2, and shows promise in treatment-resistant cases with comorbid substance use 5:

• Typical dosing would be 2-4 mg/day (based on adult data showing efficacy at these doses) 1
• It may take 6-12 weeks to show separation from placebo 6
• Monitor carefully for metabolic effects, extrapyramidal symptoms, and akathisia 1

However, the evidence-based recommendation remains: proceed to clozapine after two failed antipsychotic trials 3, 4. Clozapine with concurrent metformin should be offered to mitigate weight gain 3. Target plasma levels of 350-550 ng/mL for optimal response 3.

Monitoring Requirements for Adolescents

Regardless of medication choice, adolescents require more intensive monitoring than adults due to:

• Higher risk of extrapyramidal symptoms 4
• Developmental communication challenges in reporting side effects 4
• Greater metabolic vulnerability 4
• Need for baseline and ongoing assessment of abnormal movements, liver function, complete blood counts, and ECG 4